110 related articles for article (PubMed ID: 21566342)
41. IGF-I inhibition of apoptosis is associated with decreased expression of prostate apoptosis response-4.
Chung H; Seo S; Moon M; Park S
J Endocrinol; 2007 Jul; 194(1):77-85. PubMed ID: 17592023
[TBL] [Abstract][Full Text] [Related]
42. The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
Li M; de Graaf IA; van de Steeg E; de Jager MH; Groothuis GM
Toxicol In Vitro; 2017 Apr; 40():26-33. PubMed ID: 27939799
[TBL] [Abstract][Full Text] [Related]
43. Human CYP3A4-introduced HepG2 cells: in vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity.
Araki N; Tsuruoka S; Wang N; Hasegawa G; Yanagihara H; Ando H; Omasa T; Enosawa S; Nagai H; Fujimura A
Xenobiotica; 2008 Nov; 38(11):1355-64. PubMed ID: 18846481
[TBL] [Abstract][Full Text] [Related]
44. In vitro evaluation of cytochrome P450 induction and the inhibition potential of mitragynine, a stimulant alkaloid.
Lim EL; Seah TC; Koe XF; Wahab HA; Adenan MI; Jamil MF; Majid MI; Tan ML
Toxicol In Vitro; 2013 Mar; 27(2):812-24. PubMed ID: 23274770
[TBL] [Abstract][Full Text] [Related]
45. Aloe vera juice: IC₅₀ and dual mechanistic inhibition of CYP3A4 and CYP2D6.
Djuv A; Nilsen OG
Phytother Res; 2012 Mar; 26(3):445-51. PubMed ID: 21842479
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids.
Sun J; Sui X; Bradbury JA; Zeldin DC; Conte MS; Liao JK
Circ Res; 2002 May; 90(9):1020-7. PubMed ID: 12016269
[TBL] [Abstract][Full Text] [Related]
47. In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.
Davis JA; Rock DA; Wienkers LC; Pearson JT
Drug Metab Dispos; 2012 Oct; 40(10):1927-34. PubMed ID: 22752008
[TBL] [Abstract][Full Text] [Related]
48. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
[TBL] [Abstract][Full Text] [Related]
49. CYP2D6 is primarily responsible for the metabolism of clomiphene.
Ghobadi C; Gregory A; Crewe HK; Rostami-Hodjegan A; Lennard MS
Drug Metab Pharmacokinet; 2008; 23(2):101-5. PubMed ID: 18445989
[TBL] [Abstract][Full Text] [Related]
50. Post-receptor signal transduction and regulation of 14(R),15(S)-epoxyeicosatrienoic acid (14,15-EET) binding in U-937 cells.
Wong PY; Lai PS; Shen SY; Belosludtsev YY; Falck JR
J Lipid Mediat Cell Signal; 1997 Jul; 16(3):155-69. PubMed ID: 9246605
[TBL] [Abstract][Full Text] [Related]
51. High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method.
Yamamoto T; Suzuki A; Kohno Y
Xenobiotica; 2004 Jan; 34(1):87-101. PubMed ID: 14742138
[TBL] [Abstract][Full Text] [Related]
52. Demethylation of neferine in human liver microsomes and formation of quinone methide metabolites mediated by CYP3A4 accentuates its cytotoxicity.
Shen Q; Zuo M; Ma L; Tian Y; Wang L; Jiang H; Zhou Q; Zhou H; Yu L; Zeng S
Chem Biol Interact; 2014 Dec; 224():89-99. PubMed ID: 25451576
[TBL] [Abstract][Full Text] [Related]
53. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
[TBL] [Abstract][Full Text] [Related]
54. Role of CYP2D6 in the N-hydroxylation of procainamide.
Lessard E; Fortin A; Bélanger PM; Beaune P; Hamelin BA; Turgeon J
Pharmacogenetics; 1997 Oct; 7(5):381-90. PubMed ID: 9352574
[TBL] [Abstract][Full Text] [Related]
55. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
56. Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
Champelovier P; El Atifi M; Pautre V; Rostaing B; Berger F; Seigneurin D
Exp Hematol; 2008 Jan; 36(1):28-36. PubMed ID: 17949889
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of CYP3A4 by 6',7'-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells.
Araki N; Tsuruoka S; Hasegawa G; Yanagihara H; Omasa T; Enosawa S; Yamazoe Y; Fujimura A
J Pharm Pharmacol; 2012 Dec; 64(12):1715-21. PubMed ID: 23146034
[TBL] [Abstract][Full Text] [Related]
58. Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease.
Coin A; Pamio MV; Alexopoulos C; Granziera S; Groppa F; de Rosa G; Girardi A; Sergi G; Manzato E; Padrini R
Eur J Clin Pharmacol; 2016 Jun; 72(6):711-7. PubMed ID: 26952092
[TBL] [Abstract][Full Text] [Related]
59. The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation.
Lin XX; Lian GH; Xu Y; Zhao Q; Xiao J; Peng SF; Xiao MF; Ouyang DS; Tan ZR; Wang YC; Peng JB; Zhang W; Chen Y
Xenobiotica; 2018 Oct; 48(10):999-1005. PubMed ID: 29027845
[TBL] [Abstract][Full Text] [Related]
60. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
